Morepen Labs Q4 FY26 Results: Net Profit Up 48% YoY to ₹55.27 Cr
Morepen Laboratories reported audited standalone and consolidated financial results for Q4 FY26. Standalone net profit increased by 48% YoY to ₹55.27 crore, with total income at ₹1050.96 lakh. Consolidated net profit rose 48% YoY to ₹55.01 crore, with total income at ₹1065.67 lakh. The results were approved on May 26, 2026.
The substantial increase in profit and the clear reporting of financial results are material information for investors, likely to impact the stock price and investor sentiment.
The company reported a significant year-on-year increase in net profit for both standalone and consolidated results, indicating positive financial performance.
Morepen Laboratories Limited announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The Board of Directors approved these results on May 26, 2026.
For the fourth quarter of FY26, the company reported a net profit of ₹55.27 crore, a significant increase of 48% compared to ₹37.18 crore in the same quarter of the previous fiscal year. Total income from operations for the quarter stood at ₹1050.96 lakh.
On a consolidated basis, the net profit for the quarter ended March 31, 2026, was ₹55.01 crore, up 48% year-on-year from ₹37.18 crore in the corresponding quarter of FY25. The total income from operations for the consolidated entity was ₹1065.67 lakh.
The company also published these results in the Financial Express (English) and Jansatta (Hindi) newspapers on May 27, 2026, in compliance with SEBI regulations. The full financial results are available on the company's website and the stock exchanges' websites.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.